Positive Interim Ph 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability of PAS-004, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Announced
Dr. Kartik Krishnan, Chief Medical Officer of Pasithea, said, “The literature reports that patients with BRAF mutated cancer who progress on BRAF/MEK combination therapy have a median progression-free survival of approximately 5 months with rechallenge with BRAF/MEK combination therapy. We have observed that a number of these patients who previously progressed on prior BRAF/MEK inhibitor treatment have demonstrated stable disease on PAS-004 for greater than six months, including two patients for over one year. We believe that this demonstrates that PAS-004 is an active agent. Importantly, we continue to be encouraged by the observed adverse event (AE) profile and the ability to maintain dosing in patients over a long period of time without discontinuations. Given that we have not reached the maximum tolerated dose (MTD) and the tolerability of the doses we have evaluated to date, we have decided to continue dose escalation in the study with the introduction of our tablet formulation, while also exploring the effect of food on the PK of PAS-004 to enhance our understanding about how best to maximize the benefit of PAS-004 in long-term chronic dosing.”
Share:
More News
“This acquisition further strengthens our late-stage oncology pipeline and reflects our continued focus on bringing transformational treatments to people living with cancer,” said David Loew, CEO, Ipsen. “We are excited by the potential of navtemadlin to define a new treatment paradigm for patients with myelofibrosis who have a suboptimal response
“We are pleased to partner with Roche to explore the combination potential of EXP011 and atezolizumab for patients with SCLC and other hard-to-treat solid tumors.” said Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics. “This collaboration enables us to evaluate a differentiated immuno-oncology combination strategy to address
Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally. We believe
“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, President of Biomedical Research at Novartis. “Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism